Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia: A Role That Is Still to Be Defined

Mayo Clin Proc. 2020 Aug;95(8):1565-1566. doi: 10.1016/j.mayocp.2020.06.038.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Epistaxis
  • Heart Failure*
  • Humans
  • Telangiectasia, Hereditary Hemorrhagic* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab